MarketsNotableConfirmed
6.4
AstraZeneca Q2 earnings exceed expectations on oncology segment growth
Valor Econômico·GB·about 5 hours ago
Cavotec reported a widened operating loss of 2.2 million EUR for Q2 2026 compared to 0.7 million EUR in the same period last year. The operating margin declined to -5 percent, reflecting ongoing financial pressure despite reported increases in revenue and order intake.